News Gilead expands CAR-T deal with MaxCyte, Precision files for ... It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-sh
News NICE to reassess Pfizer blood cancer drug Company successfully appealed against rejection last summer
News Pfizer facing NICE showdown over leukaemia drug Pfizer locks horns with NICE following EU approval.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.